在免疫无细胞性贫血中,HLA I 类异基因损失和骨髓移植结果在免疫无细胞性贫血中
Yoshitaka Zaimoku1, Takamasa Katagiri2, Noriharu Nakagawa3
1Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; Department of Infection Control and Prevention, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Transplantation and cellular therapy
|November 16, 2023
概括
在接受骨髓移植 (BMT) 的无形成性贫血 (AA) 患者中,HLA I类等位基因损失没有影响整体存活率. 然而,像HLA-A*02:06或HLA-B*40:02这样的特定等位基因的丧失与改善的生存结果相关.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
背景情况:
- 通过免疫媒介获得的无形性贫血 (AA) 涉及血液形成前体细胞上HLA类I等位基因的损失,可能有助于免疫逃避.
- 虽然在免疫抑制疗法 (IST) 中研究了HLA I类等位基损失,但其对异构骨髓移植 (BMT) 的影响尚不清楚.
研究的目的:
- 调查HLAI类等位基损失 (HLA-LOH) 在获得AA患者接受异构BMT的临床影响.
主要方法:
- 在178名获得AA的患者中评估了移植前的HLA-LOH,这些患者接受了无关联的BMT (1993-2011).
- 相关联的HLA-LOH状态与日本移植注册局的临床数据.
- 对HLA-LOH阳性和匹配的阴性患者之间的结局进行了比较,并分析了特定的等位基因损失 (HLA-A*02:06,HLA-B*40:02).
主要成果:
- 在11%的患者中检测到HLA-LOH,这些患者通常有更严重的AA,并且早些时候接受了BMT.
- HLA-LOH状态没有显著影响生存,移植,移植失败或GvHD.
- 失去HLA-A*02:06或HLA-B*40:02等位基因与显著更高的5年整体存活率相关 (100%对44%).
结论:
- 虽然HLA-LOH本身并不能预测BMT的结果,但像HLA-A*02:06和HLA-B*40:02这样的特定等位基因的丧失可能表明生存益处.
- 这些发现表明,与特定的HLA等位基因损失相关的免疫病原性机制,而不是单独的基因型,影响生存率.
- 在AA病理生理学中对HLA等位基因损失的进一步研究可能会改进对BMT的患者选择.
相关概念视频
Bone Marrow Sampling and Transplants
334
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
334
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Cell-mediated Immune Responses
68.4K
Overview
68.4K
Tissue Transplantation
375
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
375
Stem Cell Therapy for Tissue Regeneration
4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K


